Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics

DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.

Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hodgkin's lymphoma Market Report
• In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
• In February 2025:- Juventas Cell Therapy Ltd.:- The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL. The study consists of screening period (8 weeks), treatment period (4 weeks), and follow-up period (2 years at most).
• The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin's Lymphoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom, and Japan from 2019 to 2032.
• According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin's disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin's disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.
• The leading Hodgkin's Lymphoma Companies such as Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, and others.
• Promising Hodgkin's Lymphoma Therapies such as HCD122, Resminostat (4SC-201), AK105, Ruxolitinib, ITF2357, Panobinostat and others.

Stay ahead in the Hodgkin's lymphoma Therapeutics Market with DelveInsight's Strategic Report @ Hodgkin's lymphoma Market Outlook- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hodgkin's lymphoma Epidemiology Segmentation in the 7MM
• Total Incident Cases of Hodgkin's Lymphoma
• Age-specific incident Cases of Hodgkin's Lymphoma
• Gender-specific incident Cases of Hodgkin's Lymphoma
• Incident Population of Relapsed/ Refractory form of Hodgkin Lymphoma
• Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)

Download the report to understand which factors are driving Hodgkin's lymphoma epidemiology trends @ Hodgkin's lymphoma Prevalence- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hodgkin's Lymphoma Marketed Drugs
Monoclonal antibodies such as Brentuximab vedotin (Adcetris), an anti-CD30 antibody attached to a chemo drug is also used to treat the condition. The antibody acts like a homing signal, bringing the chemo drug to the lymphoma cells with CD30 on them. The drug enters the cells and kills them when they try to divide into new cells. Rituximab (Rituxan) may be used to treat nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This mAb attaches to a substance called CD20 on some types of lymphoma cells. Additionally, immune checkpoint inhibitors such as Nivolumab (Opdivo) and pembrolizumab (Keytruda) are used in people with classic Hodgkin lymphoma whose cancer has grown during treatment (called refractory cancer) or has returned after other treatments have been tried (called recurrent or relapsed cancer).

Hodgkin's Lymphoma Emerging Drugs
• ADC Therapeutics is developing Camidanlumab Tesirine (ADCT-301), which is in phase II clinical developmental trial for the treatment of Relapsed/Refractory Hodgkin Lymphoma (R/R HL). ADCT-301 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax-TAC, licensed from Genmab), conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once attached to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, ADCT-301 depletes CD25-positive Tregs in the local tumor environment, which enhances immune-mediated anti-tumor activity.
• Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Binding to FcγR on macrophages has been shown to compromise the antitumor activity of PD-1 antibodies through activation of the antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene's immuno-oncology biologic program, and it could serve as a key element of their immuno-oncology combination platform. As per the company's pipeline portfolio, the drug has been filed for relapsed or refractory classical Hodgkin Lymphoma (R/R HL), which has been granted conditional approval for the treatment of patients with classical Hodgkin's lymphoma (cHL) who received at least two prior therapies by the China National Medical Products Administration. Currently, Tislelizumab is in a pivotal Phase II Hodgkin's Lymphoma clinical trial in relapsed/refractory classical Hodgkin's lymphoma (R/R cHL).

Get In-Depth Knowledge on Hodgkin's lymphoma Market Trends and Forecasts with DelveInsight @ Hodgkin's lymphoma Treatment Market- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hodgkin's lymphoma Companies
Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, and others.

Hodgkin's Lymphoma Market Outlook
For Hodgkin lymphoma, radiation is often given after chemotherapy, especially when there's a large or bulky tumor mass (usually in the chest). Radiation therapy namely Involved site radiation therapy (ISRT), Involved field radiation therapy (IFRT), Extended field radiation and total body radiation are commonly employed. Chemo for Hodgkin lymphoma combines several drugs because different drugs kill cancer cells in different ways. The combinations used to treat the condition are often referred to by abbreviations. ABVD is the most common regimen used in the United States that includes the chemotherapeutic drugs namely Adriamycin (doxorubicin), Bleomycin, Vinblastine and Dacarbazine (DTIC). Other common regimens includes BEACOPP [Bleomycin, Etoposide (VP-16), Adriamycin (doxorubicin), Cyclophosphamide, Oncovin (vincristine), Procarbazine and Prednisone], Stanford V [Doxorubicin (Adriamycin), Mechlorethamine (nitrogen mustard), Vincristine, Vinblastine, Bleomycin, Etoposide, Prednisone]. Radiation is given after chemo in the Stanford V regimen.

Unlock Strategic Insights with DelveInsight's Comprehensive Hodgkin's lymphoma Market Report @ Hodgkin's lymphoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hodgkin's lymphoma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Hodgkin's lymphoma Companies- Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, and others.
• Hodgkin's Lymphoma Therapies- HCD122, Resminostat (4SC-201), AK105, Ruxolitinib, ITF2357, Panobinostat and others.
• Hodgkin's lymphoma Market Dynamics: Hodgkin's lymphoma Market Drivers and Barriers
• Hodgkin's lymphoma Market Access and Reimbursement and Unmet Needs

Unlock Strategic Insights with DelveInsight's Comprehensive Hodgkin's lymphoma Market Report @ Hodgkin's lymphoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Report Introduction
2. Hodgkin Lymphoma : Market Overview at a Glance
3. Disease Background and Overview: Hodgkin Lymphoma
4. Epidemiology and Patient Population (7MM)
5. Hodgkin Lymphoma : Country-Wise Epidemiology
6. Treatments & Medical Practices
7. Marketed Therapies
8. Emerging Therapies
9. Hodgkin Lymphoma : Market Size
10. 7MM: Country-Wise Market Analysis
11. The United States Market Size
12. EU4 and the UK Market Size
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.